The INFORM2 Trial has officially opened in Australia. This trial is an exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with brain cancer. The trial aims to increase survival rates with the use of these two immunotherapy agents.
This is an international trial lead by the Hopp Children’s Cancer Center Heidelberg, Germany and The Perth Children’s Hospital is the first Australian site to open for recruitment. The Sydney Children’s Hospital and the Royal Children’s Hospital Melbourne will follow shortly and will join other centres in Germany, The Netherlands, Sweden, and France.
NSW Health has provided Luminesce Alliance partners, the Sydney Children’s Hospitals Network (SCHN) and the Children’s Cancer Institute (CCI) $1 million over four years to support this trial and as a means of demonstrating that NSW has the capacity and capability undertake international clinical trials of this calibre and clinical potential. The Lead Investigator is Associate Professor David Ziegler.